The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
| Autor: | Soo Kyung Kim, Chul Woo Ahn, Hae Jin Kim, Wan Sub Shim, Yong Wook Cho, Hyun Chul Lee, Sung Kil Lim, Bong Soo Cha, Kyu Yeon Hur, Seok Won Park |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Abdominal Fat Adipose tissue Fat mass Rosiglitazone chemistry.chemical_compound Endocrinology Diabetes mellitus Internal medicine medicine Humans Hypoglycemic Agents Glycemic Ultrasonography Glycated Hemoglobin business.industry General Medicine Middle Aged medicine.disease Lipid Metabolism Independent factor medicine.anatomical_structure chemistry Diabetes Mellitus Type 2 Body Composition Abdomen Regression Analysis Female Thiazolidinediones Glycated hemoglobin business medicine.drug |
| Zdroj: | European journal of endocrinology. 157(2) |
| ISSN: | 0804-4643 |
| Popis: | Objective: The goal was to investigate the interrelationships between the hypoglycemic effects of rosiglitazone and the changes in the regional adiposity of type 2 diabetic patients. Design and methods: We added rosiglitazone (4 mg/day) to 173 diabetic patients (111 males and 62 females) already taking a stable dose of conventional antidiabetic medications except for thiazolidinediones. The abdominal fat distribution was assessed by ultrasonography at baseline and 12 weeks later. Using ultrasonographic images, the s.c. and visceral fat thickness (SFT and VFT respectively) were measured. Results: Rosiglitazone treatment for 3 months improved the glycemic control. However, the response to rosiglitazone was no more than 36.4%; the deterioration of the glycemic control was found in 16.8% of subjects. In addition, rosiglitazone treatment significantly increased the body fat mass, especially the s.c. fat. However that did not alter the visceral fat content. The percentage changes in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) concentrations after treatment were inversely correlated with the increase in SFT (r=−0.327 and −0.353, Pr=−0.316 and −0.327, PPP=0.019), and the reduction in the HbA1c was related with the baseline FPG (P=0.003) and HbA1c (PP=0.010) or VFT (P=0.013). Conclusions: The increase in the s.c. fat depot after rosiglitazone treatment may be an independent factor that determines the hypoglycemic efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|